Incyte Corporation, based in Wilmington, Delaware, is a leading biopharmaceutical firm specializing in the development of innovative therapies for oncology and other critical diseases. Founded in 1991, the company has established a strong commercial presence with its flagship product, Jakafi, which is used to treat myelofibrosis and polycythemia vera, while also advancing a diverse pipeline of candidates targeting various cancer types. Incyte's dedication to precision medicine and its collaborative approach to research underscore its pivotal role in addressing unmet medical needs in the healthcare landscape. With a focus on scientific innovation, Incyte aims to enhance patient outcomes and solidify its status as a key player in biopharma.